<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28627" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ritonavir</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Talha</surname>
            <given-names>Bilal</given-names>
          </name>
          <aff>Upstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dhamoon</surname>
            <given-names>Amit S.</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bilal Talha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amit Dhamoon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28627.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ritonavir is a protease inhibitor used for the treatment of HIV/AIDS. It is seldom employed for its own antiviral activity but instead serves as a booster for other protease inhibitors. Although ritonavir was initially designed to inhibit HIV protease, studies have found that it also inhibits cytochrome P450-3A4. Because of its mechanism of action, ritonavir is currently under investigation for its use in treating some forms of cancer. In addition, it is used in combination with other medicines to treat Hepatitis C infection. This activity reviews the indications, dosage, administration, adverse event profile, mechanisms of action, toxicity, and contraindications for ritonavir as part of treating HIV/AIDS. This activity is pertinent for members of the interprofessional team involved in caring for patients with HIV/AIDS, including physicians, infectious disease specialists, nurses, pharmacists, physician assistants, and other healthcare providers.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications for ritonavir.</p></list-item><list-item><p>Outline the potential adverse effects of ritonavir.</p></list-item><list-item><p>Summarize the mechanism of action of ritonavir, both as an antiretroviral on its own and in its use with other agents.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team to enhance the care of HIV patients when dosing with ritonavir to help limit side effects and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28627&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28627">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28627.s2" sec-type="Indications">
        <title>Indications</title>
        <p>In the United States, the Food and Drug Administration (FDA)&#x000a0;approved ritonavir in 1996 to treat HIV. After&#x000a0;saquinavir, it was the second approved protease inhibitor in the United States. Although ritonavir was initially designed to inhibit&#x000a0;HIV protease, studies have found that it also inhibits&#x000a0;cytochrome P450-3A4 (CYP450-3A4), which is its chief mechanism of action. It is currently used to augment HIV treatment by increasing the bioavailability&#x000a0;of co-administered anti-retroviral (ARV) drugs. Combined with triple therapy, initial results for ritonavir showed increased CD4+ count and decreased HIV RNA levels in treatment na&#x000ef;ve patients.<xref ref-type="bibr" rid="article-28627.r1">[1]</xref>&#x000a0;</p>
        <p>In combination with other standard ARV medications, lopinavir/ritonavir has provided significant virological suppression and better immune outcomes in both treatment-naive and treatment-experienced patients.<xref ref-type="bibr" rid="article-28627.r2">[2]</xref>&#x000a0;Because of its mechanism of action, ritonavir is currently under investigation for its use in treating some forms of cancer.<xref ref-type="bibr" rid="article-28627.r3">[3]</xref>&#x000a0;In 2014, the FDA approved a combination drug of ombitasvir/paritaprevir/ritonavir and dasabuvir to treat hepatitis C virus (HCV)&#x000a0;genotype 1.<xref ref-type="bibr" rid="article-28627.r4">[4]</xref>&#x000a0;It is highly efficacious with minimal side effects. Additionally, lopinavir/ritonavir was FDA approved in early 2000.&#x000a0;</p>
        <p>In combination with&#x000a0;nirmatrelvir, ritonavir has received emergency use authorization as an investigational drug combination to treat COVID-19 in patients with mild-to-moderate severity. It is limited to the use in adults and children aged 12 years and older (weighing 88 pounds or more) with positive results of direct SARS-CoV-2 viral testing and at high risk for progression to severe COVID-19, including hospitalization or death. Some evidence exists for using ritonavir in combination with lopinavir to treat COVID-19 infection, but large clinical trials are needed to achieve more reliable results.<xref ref-type="bibr" rid="article-28627.r5">[5]</xref></p>
      </sec>
      <sec id="article-28627.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ritonavir works by binding to HIV-1 protease. HIV-1 protease causes cleavage of protein precursors generating new viral particles. Protease inhibitors disrupt this cleavage process, interrupting the production of new viral particles.<xref ref-type="bibr" rid="article-28627.r6">[6]</xref></p>
        <p>Perhaps the more important mechanism of action of ritonavir for the treatment of HIV and HCV is its inhibition of the liver enzyme cytochrome P450 3A4 (CYP450-3A4). This cytochrome pathway metabolizes other protease inhibitors. When ritonavir inhibits CYP450-3A4, the bioavailability of other antiretroviral drugs increases, and inhibition of this CYP450 pathway causes a decrease in the breakdown of ARVs, hence increasing serum drug levels. Ritonavir should be used carefully with other drugs metabolized through&#x000a0;this&#x000a0;pathway, including statins, anti-arrhythmic agents, anti-epileptic drugs, and anti-fungal agents.<xref ref-type="bibr" rid="article-28627.r7">[7]</xref></p>
      </sec>
      <sec id="article-28627.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ritonavir capsules and tablets are not bioequivalent. It is available in 100 mg tablets, capsules, powder packets, and 80 mg/ml oral solutions. Usually, it is used in the lopinavir/ritonavir combination of drugs used for HIV. The small amount of ritonavir increases the bioavailability of the lopinavir.<xref ref-type="bibr" rid="article-28627.r1">[1]</xref>&#x000a0;The standard route of administration is oral. It comes as a tablet, soft gel capsule, or oral suspension for adult and pediatric populations.<xref ref-type="bibr" rid="article-28627.r2">[2]</xref> The typical regimen is dosed at 400 mg lopinavir/100 mg&#x000a0;ritonavir orally twice daily.&#x000a0;</p>
        <p><bold>Lopinavir/Ritonavir&#x000a0;</bold><bold>Formulation&#x000a0;</bold> &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tablet:&#x000a0;</bold>100 mg/25 mg, 200 mg/50 mg</p>
          </list-item>
          <list-item>
            <p><bold>Oral Solution:&#x000a0;</bold>400 mg/100 mg per 5 mL</p>
          </list-item>
        </list>
        <p>
<bold>HIV-1</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>400 mg/100 mg orally twice daily, or 800 mg/200 mg by mouth once daily in patients with less than three lopinavir resistance-associated substitutions</p>
          </list-item>
          <list-item>
            <p>Increase the dose to 500 mg/125 mg orally twice daily in tablet formulation or 520 mg/130 mg (6.5 mL) solution by mouth twice daily if used with efavirenz, fosamprenavir, nelfinavir, or nevirapine</p>
          </list-item>
        </list>
        <p>
<bold>HIV Post-exposure Prophylaxis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>400 mg/100 mg orally twice daily</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Population</bold>
</p>
        <p>
<bold>14 days to 12 months</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>16 mg/4 mg/kg orally twice daily</p>
          </list-item>
        </list>
        <p>
<bold>Treatment na&#x000ef;ve patients, age over 13 months, less than 15 kg</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>12 mg/3 mg/kg orally twice daily or 230 mg/57.5mg/m^2</p>
          </list-item>
          <list-item>
            <p>Increase the dose to 300 mg/75 mg/m^2 when used with efavirenz, fosamprenavir, nelfinavir, or nevirapine.</p>
          </list-item>
        </list>
        <p>
<bold>Treatment na&#x000ef;ve patients, greater than 13 months, 15 to 40 kg</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>10mg/2.5 mg/kg by mouth twice daily OR 230 mg/57.5 mg/m^2</p>
          </list-item>
          <list-item>
            <p>Increase the dose to 300 mg/75 mg/m^2 when used with efavirenz, fosamprenavir, nelfinavir, or nevirapine.</p>
          </list-item>
        </list>
        <p>
<bold>Treatment-experienced patients older than 13 months, under 15 kg</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>13 mg/3.25 mg/kg orally twice a day. Max dose is 400 mg/100 mg twice daily or 300 mg/75 mg/m^2</p>
          </list-item>
          <list-item>
            <p>Increase the dose to 300 mg/75 mg/m^2 when used with efavirenz, fosamprenavir, nelfinavir, or nevirapine</p>
          </list-item>
        </list>
        <p>
<bold>Treatment-experienced patients, over 13 months, 15 to 45 kg</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>11 mg/2.75 mg/kg by mouth two times daily. Max dose is 400 mg/100 mg twice daily or 300 mg/75 mg/m^2</p>
          </list-item>
          <list-item>
            <p>Increase the dose to 300 mg/75 mg/m^2 when used with efavirenz, fosamprenavir, nelfinavir, or nevirapine.</p>
          </list-item>
        </list>
        <p>
<bold>Treatment experienced patients older than 13 months, weight greater than 45 kg</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>400 mg/100 mg/kg orally twice daily</p>
          </list-item>
          <list-item>
            <p>Increase to 500 mg/125 mg orally twice daily or 520 mg/130 mg solution twice daily with efavirenz, fosamprenavir, nelfinavir, or nevirapine.</p>
          </list-item>
        </list>
        <p>
<bold>Special Patient Population</bold>
</p>
        <p>
<bold>Patients with Hepatic Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In case of&#x000a0;moderate or severe hepatic impairment, use ritonavir with monitoring. As per the manufacturer's labeling, avoid using in patients with severe hepatic impairment.</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy Considerations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>400 mg/100 mg oral dosing twice daily</p>
          </list-item>
          <list-item>
            <p>Increase the dose to 500 mg/125 mg orally twice daily when used with efavirenz, fosamprenavir, nelfinavir, or nevirapine.</p>
          </list-item>
          <list-item>
            <p>Healthcare providers are encouraged to register patients to Antiretroviral Pregnancy Registry (APR), which monitors pregnancy outcomes in women exposed to ritonavir during pregnancy. The oral solution contains around 27% propylene glycol and 43% ethanol; hence the use is not recommended during pregnancy.</p>
          </list-item>
        </list>
        <p>
<bold>Breastfeeding Considerations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The CDC recommends against HIV-infected mothers breastfeeding their infants to prevent postnatal transmission of HIV, developing viral resistance (when HIV-negative infants), and serious adverse drug reactions. There is no information available on the effects of the ritonavir on milk production or the effects on the breastfed infant. There are no adverse reactions reported in infants.<xref ref-type="bibr" rid="article-28627.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>COVID-19 Emergency Use Authorization</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Administer 300 mg nirmatrelvir with 100 mg ritonavir by mouth twice daily (in the morning and the evening) for five days. For each dose, it is a must to take all three tablets at the same time. The dose for patients with a renal impairment needs to be adjusted based on renal function. For eGFR &#x02265;30 to &#x0003c;60 mL/min, decrease the dose to 150 mg nirmatrelvir and 100 mg ritonavir twice daily for five days. Use is not recommended for patients with eGFR &#x0003c;30 mL/min.<xref ref-type="bibr" rid="article-28627.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28627.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Ritonavir has several constitutional side effects, including malaise, dizziness, and insomnia, gastrointestinal side effects including nausea, vomiting, abdominal pain, and diarrhea, and metabolic side effects such as&#x000a0;hyperlipidemia, hypertriglyceridemia, transaminitis, and rhabdomyolysis.<xref ref-type="bibr" rid="article-28627.r2">[2]</xref> Although there are reports of QT prolongation with the use of protease inhibitors, studies have not established them as independent culprits.<xref ref-type="bibr" rid="article-28627.r10">[10]</xref></p>
        <p>Because of the metabolic side effects of ritonavir,&#x000a0;lipid-lowering agents might also be indicated along with protease inhibitors to reduce cardiovascular disease&#x000a0;risk. Other serious adverse effects are pancreatitis, diabetes mellitus, renal failure, hypersensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), hepatotoxicity, leukopenia, and neutropenia.<xref ref-type="bibr" rid="article-28627.r6">[6]</xref>&#x000a0;</p>
        <p>It requires cautious use with&#x000a0;other medications that inhibit the CYP450-3A4 enzyme, causing an increase in serum drug levels.&#x000a0;Ritonavir should also not be given to patients on pharmacological agents that act as CYP inducers. These can cause drastically reduced levels of ritonavir, resulting in potential drug resistance.<xref ref-type="bibr" rid="article-28627.r6">[6]</xref>&#x000a0;</p>
        <p>Fat Redistribution and/or accumulation, including dorsocervical fat enlargement (buffalo hump), central obesity, peripheral wasting, breast enlargement, facial wasting, and "cushingoid appearance," have been observed in patients receiving antiretroviral therapy, but causal relationships haven't been established.</p>
        <p>Reports of increased bleeding, spontaneous skin hematomas, and hemarthrosis in patients with hemophilia type A and B treated with protease inhibitors. Still, causal relationships between protease inhibitor therapy and these events are not established.</p>
        <p>Reports of varying degrees of cross-resistance among protease inhibitors have been observed. Continued use of ritonavir 1200 mg daily following a loss of viral suppression might increase the risk of cross-resistance with other protease inhibitors.</p>
      </sec>
      <sec id="article-28627.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ritonavir contraindications include patients with a known allergic reaction to either ritonavir or any of its components. Hypersensitivity reactions include Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).</p>
        <p>There is a boxed warning for drug-drug interactions of ritonavir leading to potentially serious and/or life-threatening reactions when co-administered with drugs such as antiarrhythmics (amiodarone, dronedarone, flecainide, propafenone, quinidine), sedative-hypnotics (triazolam, orally administered midazolam), HMG-COA reductase inhibitors (lovastatin, simvastatin) or an ergot alkaloid (dihydroergotamine, ergotamine, methylergonovine). Healthcare providers should review medications taken by patients before prescribing ritonavir or when prescribing other drugs to patients already taking ritonavir. It also has significant drug interaction when taken with alfuzosin, ranolazine, voriconazole, colchicine, lurasidone, pimozide, cisapride, lomitapide, or sildenafil (for the treatment of pulmonary arterial hypertension).</p>
        <p>Ritonavir is contraindicated with potent CYP3A inducers (e.g., apalutamide, St. John's wort), which can significantly reduce ritonavir plasma concentrations and may be associated with the potential for loss of virologic response, possible resistance, and cross-resistance.<xref ref-type="bibr" rid="article-28627.r6">[6]</xref></p>
      </sec>
      <sec id="article-28627.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Because ritonavir use correlates with hepatotoxicity, monitoring liver function tests before initiation of therapy,&#x000a0;2 to 8 weeks after starting treatment, and subsequently every 3 to 6 months is recommended. Ritonavir&#x000a0;has also demonstrated associations with hypercholesterolemia, so a lipid profile is recommended at&#x000a0;baseline and every 6 to 12 months. Because a rise in lipids increases the risk for cardiovascular disease, lipid-lowering agents may be required. Patients on ritonavir are also susceptible to diabetes mellitus, so recommendations include baseline fasting glucose levels followed by screening every 12 months. Although there is weak evidence of QT prolongation and Torsades de Pointes in patients on ritonavir, the measurement of electrolyte levels, including magnesium, should occur at baseline, 2 to 8 weeks after starting treatment, and every 3 to 6 months after that.<xref ref-type="bibr" rid="article-28627.r10">[10]</xref> The pediatric population should also have similar screening.</p>
        <p>The oral solution of lopinavir/ritonavir contains alcohol, so it should be avoided in neonates less than 42 weeks postmenstrual age and less than 14 days old. Infants, particularly premature infants, are at increased risk of central nervous system&#x000a0;complications.</p>
      </sec>
      <sec id="article-28627.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Because there is a small quantity of ritonavir in the combination of lopinavir/ritonavir, there are few reports of ritonavir&#x000a0;toxicity. However, a few case reports have suggested retinal toxicity secondary to ritonavir. One such case showed an improvement after discontinuing ritonavir after 2 and 4 weeks.<xref ref-type="bibr" rid="article-28627.r11">[11]</xref><xref ref-type="bibr" rid="article-28627.r12">[12]</xref></p>
        <p>Because most of the neurological and gastrointestinal side effects are directly associated with higher ritonavir concentrations,&#x000a0;the dosage should be monitored and titrated down in patients with side effects. This titration could result in increased tolerability of the drug and a decrease in treatment failure.<xref ref-type="bibr" rid="article-28627.r13">[13]</xref></p>
      </sec>
      <sec id="article-28627.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Since ritonavir is a potent&#x000a0;CYP450-3A4 inhibitor, clinicians must be cautious when adding it to a patient's regimen with multiple comorbidities and medications. Dosing, patient education, and subsequent monitoring should be the purview of an interprofessional healthcare team that includes clinicians (MDs and DOs), mid-level practitioners (NPs and PAs), nurses, and pharmacists. For instance,&#x000a0;cobicistat and ritonavir are both used&#x000a0;as pharmacokinetic boosters with similar inhibition of&#x000a0;CYP450-3A4. However, in the presence of inducers such as rifamycin or anti-convulsants, the inhibition of&#x000a0;CYP450-3A4 is markedly different.<xref ref-type="bibr" rid="article-28627.r14">[14]</xref> It might be easy to extrapolate data from ritonavir and apply it to&#x000a0;cobicistat; however, a person on a stable dose of another medication can experience an increase or decrease in serum drug concentrations. The pharmacist should perform thorough medication reconciliation and report any concerns to the prescribing clinician and nursing staff to implement corrective measures.</p>
        <p>In addition to standard drug monitoring for a particular regimen by the primary care provider/nurse practitioner, dose adjustment or additional monitoring might be necessary if a drug-drug interaction is suspected. The oncology pharmacist should assist the team in review and management.<xref ref-type="bibr" rid="article-28627.r14">[14]</xref>&#x000a0;Nursing is in the best position to evaluate and emphasize the importance of patient compliance with their antiretroviral regimen, assess treatment progress, and monitor for adverse reaction, informing the prescriber of their findings. Any antiretroviral regimen, including those with ritonavir, requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists collaborating across disciplines to achieve optimal patient results. [Level 5]</p>
      </sec>
      <sec id="article-28627.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28627&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28627">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28627/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28627">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28627.s11">
        <title>References</title>
        <ref id="article-28627.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lea</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Faulds</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Ritonavir.</article-title>
            <source>Drugs</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>541</fpage>
            <page-range>541-6; discussion 547-8</page-range>
            <pub-id pub-id-type="pmid">8891466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croxtall</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.</article-title>
            <source>Drugs</source>
            <year>2010</year>
            <month>Oct</month>
            <day>01</day>
            <volume>70</volume>
            <issue>14</issue>
            <fpage>1885</fpage>
            <page-range>1885-915</page-range>
            <pub-id pub-id-type="pmid">20836579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eatemadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aiyelabegan</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Negahdari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mazlomi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Daraee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Daraee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eatemadi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sadroddiny</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Role of protease and protease inhibitors in cancer pathogenesis and treatment.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>86</volume>
            <fpage>221</fpage>
            <page-range>221-231</page-range>
            <pub-id pub-id-type="pmid">28006747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klibanov</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Santevecchi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.</article-title>
            <source>Ann Pharmacother</source>
            <year>2015</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-81</page-range>
            <pub-id pub-id-type="pmid">25680759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotecha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Light</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Checcucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amparore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fiori</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porpiglia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elhage</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Repurposing of drugs for COVID-19: a systematic review and meta-analysis.</article-title>
            <source>Panminerva Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-114</page-range>
            <pub-id pub-id-type="pmid">33073552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kemnic</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Gulick</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <chapter-title>HIV Antiretroviral Therapy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30020680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loelius</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Lannan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Blumberg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Phipps</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro.</article-title>
            <source>Thromb Res</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>169</volume>
            <fpage>96</fpage>
            <page-range>96-104</page-range>
            <pub-id pub-id-type="pmid">30031293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Ritonavir</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iglesias</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].</article-title>
            <source>Rev Esp Quimioter</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>236</fpage>
            <page-range>236-240</page-range>
            <pub-id pub-id-type="pmid">35183067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hills-Nieminen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Protease inhibitor-associated QT interval prolongation.</article-title>
            <source>Ann Pharmacother</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>1544</fpage>
            <page-range>1544-50</page-range>
            <pub-id pub-id-type="pmid">22128044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Poblete</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Freilich</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Zarbin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bhagat</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Retinal toxicity with Ritonavir.</article-title>
            <source>Int J Ophthalmol</source>
            <year>2016</year>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>640</fpage>
            <page-range>640-2</page-range>
            <pub-id pub-id-type="pmid">27162744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Louie</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Retinal Toxicity Secondary to Ritonavir.</article-title>
            <source>Optom Vis Sci</source>
            <year>2019</year>
            <month>May</month>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>376</fpage>
            <page-range>376-381</page-range>
            <pub-id pub-id-type="pmid">31046022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gatti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Biagio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casazza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Pascalis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bassetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cruciani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bassetti</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring.</article-title>
            <source>AIDS</source>
            <year>1999</year>
            <month>Oct</month>
            <day>22</day>
            <volume>13</volume>
            <issue>15</issue>
            <fpage>2083</fpage>
            <page-range>2083-9</page-range>
            <pub-id pub-id-type="pmid">10546861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28627.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tseng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.</article-title>
            <source>Ann Pharmacother</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>51</volume>
            <issue>11</issue>
            <fpage>1008</fpage>
            <page-range>1008-1022</page-range>
            <pub-id pub-id-type="pmid">28627229</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
